KeyCorp Raises Certara (NASDAQ:CERT) Price Target to $18.00

Certara (NASDAQ:CERT - Free Report) had its price target hoisted by KeyCorp from $15.00 to $18.00 in a research report report published on Wednesday morning,Benzinga reports. KeyCorp currently has an overweight rating on the stock.

CERT has been the subject of a number of other reports. Robert W. Baird lifted their price target on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. William Blair reiterated a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Stephens restated an "overweight" rating and issued a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. TD Cowen started coverage on shares of Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective for the company. Finally, Barclays decreased their target price on shares of Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Certara has a consensus rating of "Moderate Buy" and an average target price of $15.17.

Certara Stock Performance

NASDAQ:CERT traded up $0.62 during mid-day trading on Wednesday, reaching $14.15. 2,114,112 shares of the company's stock were exchanged, compared to its average volume of 1,188,632. Certara has a one year low of $8.64 and a one year high of $17.94. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The business's fifty day simple moving average is $11.62 and its two-hundred day simple moving average is $11.46. The firm has a market capitalization of $2.28 billion, a PE ratio of -70.75, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64.

Institutional Investors Weigh In On Certara

A number of hedge funds have recently made changes to their positions in the stock. ArrowMark Colorado Holdings LLC lifted its stake in Certara by 164.2% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock valued at $66,171,000 after purchasing an additional 3,861,674 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Certara by 864.0% in the 4th quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company's stock valued at $40,253,000 after acquiring an additional 3,387,590 shares during the last quarter. Mackenzie Financial Corp bought a new stake in Certara during the 4th quarter worth $17,852,000. Brown Brothers Harriman & Co. increased its holdings in Certara by 63.8% in the 4th quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock worth $40,668,000 after purchasing an additional 1,487,998 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in Certara by 169.0% in the fourth quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock valued at $21,248,000 after purchasing an additional 1,253,385 shares during the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.